Table 3 Enhancement of treatment during MCCAED treatment on follow-up measures

BMI

20.68 (2.67)

19.18 (3.34)

F(1, 72) = 3.90, p = .052, d = .50

EDE-Q global scores

1.68 (1.53)

1.92 (1.63)

F(1, 106) = 0.50, p = .48, d = .16

WSAS scores

7.96 (9.20)

10.44 (9.42)

F(1, 104) = 1.00, p = .32, d = .27

Menstrual Status

  Irregular Periods/amenorrhea

8 (7.2%)

7 (25.0%)

χ² (1, 104) = 3.47, p = .06

  Regular periods/other

68 (92.8%)

21 (75.0%)

Further ED treatment

  No or single brief intervention

74 (84.2%)

22 (68.8%)

χ² (1, 119) = 3.99, p = .046

  Repeat or more than 6-month intervention (incl. day or inpatient)^a

13 (15.8%)

10 (31.3%)

MH difficulties

  MH diagnoses

46 (53.5%)

17 (53.1%)

χ² (1, 115) = 0.23, p = .63

  No MH diagnoses

40 (46.5%)

15 (46.9%)

Further MH treatment

  No or single brief intervention

57 (67.1%)

20 (64.5%)

χ² (2, 116) = 3.27, p = .16

  Repeat or more than 6-month intervention

21(24.7%)

5 (16.1%)

  Day or inpatient treatment

7 (8.2%)

6 (19.4%)

General well-being

  Generally well

51 (61.4%)

13 (48.2%)

χ² (2, 110) = 3.90, p = .14

  Some minor concerns

25 (30.2%)

8 (29.6%)

  Some significant concerns

7 (8.4%)

6 (22.2%)

Social well-being

  Generally well

58 (69.9%)

16 (59.3%)

χ² (2, 110) = 1.15, p = .56

  Some minor concerns

15 (18.1%)

6 (22.2%)

  Some significant concerns

10 (12.0%)

5 (18.5%)